Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 138 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Reflections from our chief scientist: The rise of the whole organism February 4, 2022 NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in... May 8, 2024 Apalutamide Plus ADT Provides Significant Improvement in Overal Survival and Delays... May 6, 2021 Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated... September 27, 2021 Load more HOT NEWS A Nurse’s Love For Oncology Patients Elderly Woman Seeks Trick-Or-Treaters Who Surprised Her With Gifts The Day... Even If Insured, People with Advanced Cancer Often Face Financial Problems The long road to targeting the holy grail of the immune...
